What PHQ-9 Score Change Counts as Real Ketamine Improvement

A drop of roughly 5 points on the PHQ-9 is the threshold most depression researchers treat as a minimal clinically important difference (MCID), the smallest change a patient and clinician would likely notice as real improvement rather than day-to-day noise. The Patient Health Questionnaire-9 (PHQ-9) is a 9-item self-report scale that scores depression symptom severity over the prior two weeks, with each item rated 0 to 3 for a total range of 0 to 27. For patients and caregivers tracking response to low-dose ketamine, the practical question is less about hitting a single magic number and more about whether the trend over several sessions crosses that 5-point line and holds.

How the PHQ-9 thresholds break down

The PHQ-9, developed and validated through primary-care research and available through the official PHQ screener materials, sorts total scores into severity bands: 0 to 4 is minimal, 5 to 9 is mild, 10 to 14 is moderate, 15 to 19 is moderately severe, and 20 to 27 is severe. Three numbers matter most when judging whether a change is meaningful:

• MCID (about 5 points): the smallest score drop generally considered noticeable and clinically relevant, not just measurement variability.
• Response (≥50% reduction): the standard definition used across depression trials to say a treatment produced a substantial effect.
• Remission (score under 5): the threshold indicating symptoms have returned to a non-depressed range, not that depression is "cured."

These definitions matter when you're deciding whether a drop from, say, 18 to 14 after a few low-dose sessions is worth reporting to your prescriber as progress, or whether it still falls inside normal week-to-week fluctuation. For a fuller picture of how clinicians define success over time, see ketamine remission criteria for depression.

Why ketamine evidence doesn't map cleanly onto these thresholds

These MCID, response, and remission thresholds come from depression-treatment research broadly, not from studies built around low-dose ketamine protocols specifically. Esketamine (Spravato), the only ketamine-related treatment with FDA approval for treatment-resistant depression, was evaluated in its pivotal trials using the Montgomery-Åsberg Depression Rating Scale (MADRS), a clinician-rated scale, not the self-reported PHQ-9. Off-label low-dose ketamine for depression or pain is typically monitored with whichever scale a prescriber's clinic chooses, and PHQ-9 is common because it's quick and validated for general depression tracking, but it was not built to capture ketamine's distinct pattern of rapid, sometimes transient mood change.

That distinction matters for two reasons. Firstketamine dissociation and antidepressant response research suggests the drug's acute dissociative effects can correlate with mood improvement in some studies, which may produce a sharp single-session PHQ-9 drop that doesn't reflect a stable shift. Second, low-dose protocols vary widely in dose, route, and session spacing, and the published evidence on how durable any given score change is remains limited, graded as moderate at best for short-term response and weak for long-term maintenance outcomes. Patients being considered for a protocol should review low-dose ketamine clinical eligibility criteria with a prescriber rather than relying on a single scale score.

Tracking score change in practice

Because low-dose ketamine's effects can appear quickly and fade, a single baseline-to-follow-up comparison tells you less than a running log. Most protocols call for a baseline PHQ-9 before the first session, then repeat administration at defined intervals, weekly during an induction phase, and before each maintenance session afterward. Reviewing the pattern across several data points, rather than any one number, is how prescribers distinguish a real trend from noise. If you're unsure how often to reassess or what to bring to a follow-up visitquestions to ask at a ketamine dosing follow-up covers what to raise with your clinician, and how to track symptoms between ketamine treatments walks through a practical logging routine. Older adults and patients on multiple medications should also weigh score tracking alongside the broader safety picture in ketamine therapy for older adults safety.